

DAFTAR PUSTAKA

1. Sugihantono A, Burhan E, Susanto AD, Damayanti T, Wiyono WH, Prasenhadi P, et al. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). 5th ed. Kementerian Kesehatan RI; 2020. h 1–214.
2. Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. 2020;7(1): p45–67.
3. Yuniastuti E, Karjadi TH, Widhani A, Mahdi HIS, Sundari S, Hapsari AF, et al. Incidence and severity prediction score of COVID-19 in people living with HIV (SCOVHIV): experience from the first and second waves of the pandemic in Indonesia. AIDS Res Ther. 2022 Dec 1;19(1) p1-17.
4. Susilo A, Martin Rumende C, Pitoyo CW, Djoko Santoso W, Yulianti M, Sinto R, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia [Internet]. 2020;7(1):h45–67.
5. Levani Y, Prastya AD, Mawaddatunnadila S. Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. Jurnal Kedokteran dan Kesehatan. 2021;17(1):h44–57.
6. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15; 395(10223):p470–3.
7. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. J Clin Med. 2020 May 20;9(5):p 1548-67.
8. Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine. 2020;99(47):p23315–36.

9. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. *Clinical Infectious Diseases*. 2020 Nov 5;71(8):p1937–42.
10. Wang H, Luo S, Shen Y, Li M, Zhang Z, Dong Y, et al. Multiple Enzyme Release, Inflammation Storm and Hypercoagulability Are Prominent Indicators For Disease Progression In COVID-19: A Multi-Centered, Correlation Study with CT Imaging Score. *SSRN Electronic Journal*. 2020;1–21.
11. Shen Y, Cheng C, Zheng X, Jin Y, Duan G, Chen M, et al. Elevated procalcitonin is positively associated with the severity of covid-19: A meta-analysis based on 10 cohort studies. *Medicina (Lithuania)*. 2021;57(6):p 57-71.
12. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Vol. 505, *Clinica Chimica Acta*. Elsevier B.V.; 2020. p 190–1.
13. Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. *Ann Transl Med*. 2020;8(9):p 610-8.
14. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis*. 2018;18(1):p 95–107.
15. Purwitasari M, Burhan E, Soepandi PZ. Peranan Prokalsitonin pada Pneumonia Komunitas. *The Indonesian Journal of Infectious Diseases*. 2017 Nov 5;2(2):h 33–41.

16. Ahmed S, Jaffri L, Hoodbhoy Z, Siddiqui I. Prognostic value of serum procalcitonin in covid-19 patients: A systematic review. *Indian Journal of Critical Care Medicine*. 2021;25(1):p 77–84.
17. Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest*. 2020;50(10):p 10-28.
18. Heer RS, Mandal AKJ, Kho J, Szawarski P, Csabi P, Grenshaw D, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. *Ann Clin Biochem*. 2021;58:p 520–7.
19. May M, Chang M, Dietz D, Shoucri S, Laracy J, Sobieszczyk ME, et al. Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019. *Antimicrob Agents Chemother*. 2021;65(4).p 1-18
20. Aon M, Alsaeedi A, Alzafiri A, Ibrahim MM, Al-Shammari A, Al-Shammari O, et al. The Association between Admission Procalcitonin Level and The Severity of COVID-19 Pneumonia: A Retrospective Cohort Study. *Medicina (Lithuania)*. 2022 Oct 1;58(10).p 1-12
21. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *Clinica Chimica Acta*. 2020 Jun;505:p 190–1.
22. Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest*. 2020 Oct 1;50(10). p 1-13
23. Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. *Int J Med Sci*. 2020;17(16):p 2468–76.
24. Aon M, Alsaeedi A, Alzafiri A, Ibrahim MM, Al-Shammari A, Al-Shammari O, et al. The Association between Admission

- Procalcitonin Level and The Severity of COVID-19 Pneumonia: A Retrospective Cohort Study. *Medicina (B Aires)*. 2022;58(10).p 1-16
25. Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. *Int J Med Sci*. 2020;17(16):p 2468–76.
 26. Morfi CW. Kajian Terkini CoronaVirus Disease 2019 (COVID-19). *Jurnal Ilmu Kesehatan Indonesia*. 2020 Mar 21;1(1).
 27. Medison I, Chicy Widya Morfi, Elsesmita Elsesmita, Diana Nur Asrini, Hendris Utama Citra Wahyudin, Ahmad Junaidi, et al. Relationship between Initial CT Value, Inflammatory Markers, and Onset of Clinical Symptoms with Outcomes of Treatment Outcomes of COVID-19 Patients at Dr. M. Djamil General Hospital Padang. *Bioscientia Medicina: Journal of Biomedicine and Translational Research*. 2022 Apr 25;6(6):p 1914–28.
 28. World Health Organization. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva: World Health Organization. Geneva, Switzerland; 2020.
 29. Worldometer. Coronavirus Statistic [Internet]. Worldometer. 2020 [cited 2022 Oct 10]. Available from: worldometers.info/coronavirus/country/indonesia/
 30. Belmehdi O, Hakkour M, el ON, Balahbib A, Guaouguaou FE, Benali T, et al. Molecular Structure, Pathophysiology, and Diagnosis of COVID-19. *Biointerface Res Appl Chem*. 2020;14:3. p 1-18
 31. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. *Ann Transl Med*. 2020;8(11):p 693.
 32. Monica M, Kurniawan A. Coronavirus Disease 2019 and Gastrointestinal Involvement: A Systematic Review. *Medicinus*. 2021;8(2):p 62–72.

33. Salehi S, Abedi A, Balakrishnan S, Gholamrezaezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *American Journal of Roentgenology*. 2020 Jul;215(1):87–93.
34. Cleland DA, Eranki AP. Procalcitonin. *StatPearls* [Internet] [Internet]. 2022 Aug 8 [cited 2023 Apr 17]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539794/>
35. Memar MY, Varshochi M, Shokouhi B, Asgharzadeh M, Kafil HS. Procalcitonin: The marker of pediatric bacterial infection. *Biomedicine and Pharmacotherapy*. 2017;96:p 936–43.
36. Karakioulaki M, Stolz D. The Case of Procalcitonin for Lower Respiratory Tract Infections. *Barcelona Respiratory Network*. 2021;5(4):4. p 1-13
37. Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. *Clinical Biochemist Reviews*. 2017;38(2):p 59–68.
38. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents*. 2020 Aug;56(2):p 106051.
39. Memar MY, Varshochi M, Shokouhi B, Asgharzadeh M, Kafil HS. Procalcitonin: The marker of pediatric bacterial infection. *Biomedicine & Pharmacotherapy*. 2017 Dec;96:p 936–43.
40. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet*. 1993 Feb;341(8844):p 515–8.
41. Hatzistilianou M. Diagnostic and Prognostic Role of Procalcitonin in Infections. *The Scientific World JOURNAL*. 2010;10:1941–6.
42. Becker KL, Snider R, Nysten ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *Br J Pharmacol*. 2010 Jan;159(2):p 253–64.
43. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in

- acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis.* 2018 Jan;18(1):p 95–107.
44. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet.* 1993;341(8844):p 515–8.
45. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a Marker for the Detection of Bacteremia and Sepsis in the Emergency Department. *Am J Clin Pathol.* 2011 Feb 1;135(2):p 182–9.
46. Oussalah A, Ferrand J, Filhine-Tresarrieu P, Aissa N, Aimone-Gastin I, Namour F, et al. Diagnostic Accuracy of Procalcitonin for Predicting Blood Culture Results in Patients with Suspected Bloodstream Infection. *Medicine (United States).* 2015;94(44):p1774-81.
47. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *Journal of Clinical Investigation.* 2020 Apr 13;130(5):p 2620–9.
48. van Berkel M, Kox M, Frenzel T, Pickkers P, Schouten J, van Berkel M, et al. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? *Crit Care.* 2020 Dec 6;24(1):p 600-7.
49. Feng T, James A, Doumlele K, White S, Twardzik W, Zahid K, et al. Procalcitonin Levels in COVID-19 Patients Are Strongly Associated with Mortality and ICU Acceptance in an Underserved, Inner City Population. *Medicina (B Aires).* 2021 Oct 1.57(10). p 1-14
50. Williams P, McWilliams C, Soomro K, Harding I, Gurney S, Thomas M, et al. The dynamics of procalcitonin in COVID-19 patients admitted to Intensive care unit - a multi-centre cohort study in the South West of England, UK. Vol. 82, *Journal of Infection.* W.B. Saunders Ltd; 2021. p 24–6.

51. Lugito NPH. Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or –justll a marker of bacterial coinfection? *Curr Res Transl Med*. 2021 May;69(2):p 103289-91.
52. Dolci A, Robbiano C, Aloisio E, Chibireva M, Serafini L, Falvella FS, et al. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2021 Feb 23;59(2):p 433–40.
53. Surendra H, Elyazar IRF, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg Health West Pac*. 2021 Mar;9:p 10108-11.
54. Wilson RF, Sharma AJ, Schluetchermann S, Currie DW, Mangan J, Kaplan B, et al. Factors Influencing Risk for COVID-19 Exposure Among Young Adults Aged 18–23 Years — Winnebago County, Wisconsin, March–July 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(41):p1497–502.
55. Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. *PLoS One*. 2022 May 1;17(5 May).
56. Malmgren J, Imon ID, Boya G, Imon H, Kaplan G. Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March—August 2020. 2021 *PLOS ONE* 16(3): e0243042
57. Al-Mudhaffer RH, Ahjel SW, Hassan SM, Mahmood AA, Hadi NR. Age Distribution of Clinical Symptoms, Isolation, Co-morbidities and Case Fatality Rate of COVID-19 Cases in Najaf City, Iraq. *Med Arch*. 2020 Oct 1;74(5):p 363–7.
58. Khan MS, Dogra R, Miriyala LKV, Salman FNU, Ishtiaq R, Patti DK, et al. Clinical characteristics and outcomes of patients with

- Corona Virus Disease 2019 (COVID-19) at Mercy Health Hospitals, Toledo, Ohio. *PLoS One*. 2021 Apr 1;16(4 April). p 1-17
59. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin- 6 in monitoring severe case of coronavirus disease 2019. *EMBO Mol Med*. 2020 Jul 7;12(7). p 1-8
60. Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, Madrazo M, Carmona M, Piles-Roger L, et al. COVID-19 in older adults: What are the differences with younger patients? *Geriatr Gerontol Int*. 2021;21(1):p 60–5.
61. Luca N, Federico R, Arianna G, Dario P, Davide C, Giovanni S, et al. At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. *Panminerva Med*. 2021;63(1):p 51–61.
62. Ticinesi A, Nouvenne A, Prati B, Guida L, Parise A, Cerundolo N, et al. The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia. *Mediators Inflamm*. 2021;2021.p 1-8
63. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. *Eur Respir J*. 2020;55(5).p1-6
64. Fortunato F, Martinelli D, Lo Caputo S, Santantonio T, Dattoli V, Lopalco PL, et al. Sex and gender differences in COVID-19: an Italian local register-based study. *BMJ Open*. 2021;11(10). p 1-9
65. Pettit NN, MacKenzie EL, Ridgway JP, Pursell K, Ash D, Patel B, et al. Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID-19. *Obesity (Silver Spring)*. 2020 Oct 1;28(10):p 1806–10.
66. Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early

- phase of the pandemic. *PLoS One*.2022 May 1 [cited 2023 Mar 27];17(5):e0268119.
67. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. *BMJ Open*. 2020;10(10):e040129.
 68. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study. *BMC Pulm Med*. 2021;21(1).p 1-9
 69. Pitre T, Jones A, Su J, Helmeczi W, Xu G, Lee C, et al. Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study. *Intern Emerg Med*.2021;16(6):p 1573–82.
 70. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med*. 2020;2(8):p 1069–76.
 71. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):p 497–506.
 72. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. *Expert Rev Anti Infect Ther*. 2021;19(7):877–88.
 73. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *Int J Infect Dis*. 2020;99:p 47–56.
 74. Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. *mBio*. 2021.12(1):p 1–12.

75. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020 Jul 1;146(1):110–8.
76. Gong J, Dong H, Xia QS, Huang Z yi, Wang D kun, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. *BMC Infect Dis*. 2020.20(1). p 1-12
77. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study *BMJ* 2020; p 368-80 .
78. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents*. 2020;56(2). p1-9
79. Richards O, Pallmann P, King C, Cheema Y, Killick C, Thomas-Jones E, et al. Procalcitonin increase is associated with the development of critical care-acquired infections in covid-19 ards. *Antibiotics*. 2021;10(11). p1-7
80. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, Da Silva J, et al. Morbidity and Mortality Weekly Report Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19-Georgia, March 2020. *2019*;69(18). p-18
81. Biswas M, Rahaman S, Kumar Biswas T, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Meta-Analysis Intervirology*.2019;64:p36–47.
82. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*. 2020;323(18):1775–6.
83. Bahl A, Van Baalen MN, Ortiz L, Chen NW, Todd C, Milad M, et al. Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. *Intern Emerg Med*. 2020 Nov 1 [cited 2023;15(8):p 1485-93.

84. Nicholson CJ, Wooster L, Sigurslid HH, Li RH, Jiang W, Tian W, et al. Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores. *EClinicalMedicine*. 2021 Mar 1;33.
85. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of IL-6, CRP, and PCT in patients with COVID-19. *J Clin Virology*. 2020;p7–15.
86. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–9.
87. Kumar A, Karn E, Trivedi K, Kumar P, Chauhan G, Kumari A, et al. Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis. *PLoS One*. 2022 Sep 1;17(9 9).
88. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). *medRxiv*.2020.(20):p 21832-42.
89. Tong-Minh K, van der Does Y, Engelen S, de Jong E, Ramakers C, Gommers D, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. *BMC Infect Dis*. 2022;22(1). p 1-8
90. Dolci A, Robbiano C, Aloisio E, Chibireva M, Serafini L, Falvella FS, et al. Searching for a role of procalcitonin determination in COVID-19: A study on a selected cohort of hospitalized patients. *Clin Chem Lab Med*. 2021;59(2):p433–40.
91. Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). *Clinica Chimica Acta*. 2020;510:p35–46.

92. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*. 2020;158(1):p 97–105.
93. Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. *Int J Med Sci*. 2020; (16):2468–76.
94. Jackson I, Jaradeh H, Aurit S, Aldamen A, Narechania S, Destache C, et al. Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19. *International Journal of Infectious Diseases*. 2022;119:47–52.
95. Ahmed S, Jafri L, Hoodbhoy Z, Siddiqui I. Prognostic value of serum procalcitonin in covid-19 patients: A systematic review. Vol. 25, *Indian Journal of Critical Care Medicine*. Jaypee Brothers Medical Publishers (P) Ltd; 2021. p. 77–84.
96. Zare ME, Wang Y, Kansestani AN, Almasi A, Zhang J. Procalcitonin Has Good Accuracy for Prognosis of Critical Condition and Mortality in COVID-19: A Diagnostic Test Accuracy Systematic Review and Meta-analysis. *Iran J Allergy Asthma Immunol*. 2020;19(6):557–69.

